REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for REGENXBIO in a report issued on Thursday, November 7th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will post earnings per share of ($4.92) for the year, up from their previous forecast of ($4.99). HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for REGENXBIO's current full-year earnings is ($4.77) per share. HC Wainwright also issued estimates for REGENXBIO's Q4 2024 earnings at ($1.33) EPS, Q1 2025 earnings at ($1.35) EPS, Q2 2025 earnings at $2.65 EPS, Q3 2025 earnings at ($1.34) EPS, Q4 2025 earnings at ($1.34) EPS and FY2025 earnings at ($1.39) EPS.
A number of other brokerages have also issued reports on RGNX. Chardan Capital reissued a "buy" rating and set a $52.00 target price on shares of REGENXBIO in a research note on Tuesday, October 22nd. Raymond James reissued an "outperform" rating and set a $18.00 price objective on shares of REGENXBIO in a research report on Thursday, October 10th. StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, September 20th. Finally, Barclays reduced their price objective on REGENXBIO from $55.00 to $50.00 and set an "overweight" rating for the company in a research report on Monday, August 5th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $35.55.
Read Our Latest Stock Report on RGNX
REGENXBIO Stock Performance
NASDAQ:RGNX traded up $0.40 during mid-day trading on Monday, hitting $11.56. 723,586 shares of the company's stock traded hands, compared to its average volume of 599,147. REGENXBIO has a 1 year low of $8.53 and a 1 year high of $28.80. The firm's 50 day simple moving average is $10.58 and its 200 day simple moving average is $12.44. The company has a market cap of $572.68 million, a PE ratio of -2.22 and a beta of 1.23.
Hedge Funds Weigh In On REGENXBIO
A number of large investors have recently bought and sold shares of RGNX. Integral Health Asset Management LLC increased its holdings in REGENXBIO by 25.0% during the 2nd quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company's stock worth $11,115,000 after purchasing an additional 190,000 shares during the period. Quest Partners LLC raised its holdings in shares of REGENXBIO by 11,731.0% in the second quarter. Quest Partners LLC now owns 42,000 shares of the biotechnology company's stock valued at $491,000 after acquiring an additional 41,645 shares in the last quarter. ProShare Advisors LLC lifted its stake in REGENXBIO by 8.3% in the first quarter. ProShare Advisors LLC now owns 11,384 shares of the biotechnology company's stock worth $240,000 after acquiring an additional 874 shares during the period. Squarepoint Ops LLC grew its holdings in REGENXBIO by 630.9% during the 2nd quarter. Squarepoint Ops LLC now owns 146,259 shares of the biotechnology company's stock worth $1,711,000 after acquiring an additional 126,249 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in REGENXBIO during the 2nd quarter valued at about $494,000. Hedge funds and other institutional investors own 88.08% of the company's stock.
Insider Activity at REGENXBIO
In related news, Director Argeris N. Karabelas sold 10,000 shares of the firm's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $11.56, for a total value of $115,600.00. Following the completion of the transaction, the director now directly owns 11,286 shares of the company's stock, valued at approximately $130,466.16. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 13.13% of the stock is owned by corporate insiders.
REGENXBIO Company Profile
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
See Also
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
